Answers are grounded in this paper and cite their sources.
Transforming growth factor-β1 (TGF-β1) promotes immunosuppression in the tumor microenvironment via the GARP-latent TGF-β1 complex on regulatory T cells. JYB1907 is a humanized IgG4 monoclonal antibody targeting this complex. Preclinically, JYB1907 bound GARP-latent TGF-β1 complex with high affinity and specificity, inhibited the release of TGF-β1, and showed monotherapy antitumor activity and enhanced anti-PD-1 combination activity in humanized mouse models. Despite binding to platelets that constitutively express the GARP-latent TGF-β1 complex, it did not induce activation. In a first-in-human phase I dose-escalation trial (ClinicalTrials.gov identifier: NCT05821595; registered 20 April 2023 under the title “JYB1907 in Subjects With Advanced Solid Tumors”), patients with advanced solid tumors received intravenous JYB1907 (0.5-30 mg/kg every 3 weeks). No dose-limiting toxicities occurred; the maximum tolerated dose was not reached. The most common treatment-emergent adverse events were grade 1-2 elevated D-dimer (50.0%), anemia (35.7%), and increased C-reactive protein (28.6%). Pharmacokinetics were dose-proportional with a long half-life (8-16 days). No anti-drug antibodies were detected. Disease control (stable disease) was achieved in 27.3% of evaluable patients; median progression-free survival was 42 days. JYB1907 demonstrated a manageable safety profile and favorable pharmacokinetics, supporting its further development in combination therapies.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: